Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
BACKGROUND: To evaluate long-term outcome of myeloablative allogeneic stem cell transplantation (allo-SCT) (MAC) versus reduced-intensity allo-SCT (RIC) in patients with relapsed/refractory Hodgkin's lymphoma (HL) in recent years. - PATIENTS AND METHODS: A total of 312 patients (63 MAC and 249...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
29 August 2016
|
| In: |
Annals of oncology
Year: 2016, Jahrgang: 27, Heft: 12, Pages: 2251-2257 |
| ISSN: | 1569-8041 |
| Online-Zugang: |
|
| Verfasserangaben: | S. Genadieva-Stavrik, A. Boumendil, P. Dreger, K. Peggs, J. Briones, P. Corradini, A. Bacigalupo, G. Socié, F. Bonifazi, H. Finel, A. Velardi, M. Potter, B. Bruno, L. Castagna, R. Malladi, N. Russell and A. Sureda |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1699206740 | ||
| 003 | DE-627 | ||
| 005 | 20230427032032.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200602s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdw421 |2 doi | |
| 035 | |a (DE-627)1699206740 | ||
| 035 | |a (DE-599)KXP1699206740 | ||
| 035 | |a (OCoLC)1341327262 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Genadieva-Stavrik, Sonja |e VerfasserIn |0 (DE-588)1208658115 |0 (DE-627)1694996948 |4 aut | |
| 245 | 1 | 0 | |a Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years |b a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation |c S. Genadieva-Stavrik, A. Boumendil, P. Dreger, K. Peggs, J. Briones, P. Corradini, A. Bacigalupo, G. Socié, F. Bonifazi, H. Finel, A. Velardi, M. Potter, B. Bruno, L. Castagna, R. Malladi, N. Russell and A. Sureda |
| 264 | 1 | |c 29 August 2016 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 02.06.2020 | ||
| 520 | |a BACKGROUND: To evaluate long-term outcome of myeloablative allogeneic stem cell transplantation (allo-SCT) (MAC) versus reduced-intensity allo-SCT (RIC) in patients with relapsed/refractory Hodgkin's lymphoma (HL) in recent years. - PATIENTS AND METHODS: A total of 312 patients (63 MAC and 249 RIC) with relapsed/refractory HL who received allo-SCT between 2006 and 2010 and were reported to the EBMT Database were included in the study. - RESULTS: With a median follow-up for alive patients of 56 (26-73) months, there were no significant differences in non-relapse mortality (NRM) between MAC and RIC. Relapse rate (RR) was somewhat lower in the MAC group (41% versus 52% at 24 months, P = 0.16). This lower RR translated into a marginal improvement in event-free survival (EFS) for the MAC group (48% versus 36% at 24 months, P = 0.09) with no significant differences in overall survival (73% for MAC and 62% for RIC at 24 months, P = 0.13). Multivariate analysis after adjusting for disease status at the time of allo-SCT showed that the use of MAC was of borderline statistical significance for predicting a lower RR and EFS [HR 0.7, 95% CI (0.5-1.0), P = 0.1] and [HR 0.7, 95% CI (0.5-1.0), P = 0.07], respectively, after allo-SCT. - CONCLUSIONS: With modern transplant practices, the NRM associated with MAC for HL has strongly decreased, resulting into non-significant improvement of EFS because of a somewhat better disease control compared with RIC transplants. The intensity of conditioning regimens should be considered when designing individual allo-SCT strategies or clinical trials in patients with relapsed/refractory HL. | ||
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Aged | |
| 650 | 4 | |a allogeneic stem cell transplantation | |
| 650 | 4 | |a Bone Marrow | |
| 650 | 4 | |a conditioning regimen | |
| 650 | 4 | |a Disease-Free Survival | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Graft vs Host Disease | |
| 650 | 4 | |a Hodgkin Disease | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Male | |
| 650 | 4 | |a Neoplasm Recurrence, Local | |
| 650 | 4 | |a relapsed/refractory Hodgkin's lymphoma | |
| 650 | 4 | |a Retrospective Studies | |
| 650 | 4 | |a Stem Cell Transplantation | |
| 650 | 4 | |a Transplantation Conditioning | |
| 650 | 4 | |a Transplantation, Homologous | |
| 650 | 4 | |a Treatment Outcome | |
| 700 | 1 | |a Boumendil, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 700 | 1 | |a Peggs, K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Briones, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Corradini, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bacigalupo, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Socié, G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bonifazi, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Finel, H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Velardi, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Potter, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bruno, B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Castagna, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Malladi, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Russell, N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sureda, A. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 27(2016), 12, Seite 2251-2257 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation |
| 773 | 1 | 8 | |g volume:27 |g year:2016 |g number:12 |g pages:2251-2257 |g extent:7 |a Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation |
| 951 | |a AR | ||
| 992 | |a 20200602 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 999 | |a KXP-PPN1699206740 |e 3681614148 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["S. Genadieva-Stavrik, A. Boumendil, P. Dreger, K. Peggs, J. Briones, P. Corradini, A. Bacigalupo, G. Socié, F. Bonifazi, H. Finel, A. Velardi, M. Potter, B. Bruno, L. Castagna, R. Malladi, N. Russell and A. Sureda"]},"person":[{"family":"Genadieva-Stavrik","display":"Genadieva-Stavrik, Sonja","role":"aut","given":"Sonja"},{"display":"Boumendil, A.","role":"aut","given":"A.","family":"Boumendil"},{"family":"Dreger","display":"Dreger, Peter","given":"Peter","role":"aut"},{"display":"Peggs, K.","role":"aut","given":"K.","family":"Peggs"},{"display":"Briones, J.","given":"J.","role":"aut","family":"Briones"},{"role":"aut","given":"P.","display":"Corradini, P.","family":"Corradini"},{"family":"Bacigalupo","display":"Bacigalupo, A.","role":"aut","given":"A."},{"family":"Socié","role":"aut","given":"G.","display":"Socié, G."},{"display":"Bonifazi, F.","given":"F.","role":"aut","family":"Bonifazi"},{"display":"Finel, H.","given":"H.","role":"aut","family":"Finel"},{"given":"A.","role":"aut","display":"Velardi, A.","family":"Velardi"},{"family":"Potter","role":"aut","given":"M.","display":"Potter, M."},{"display":"Bruno, B.","given":"B.","role":"aut","family":"Bruno"},{"role":"aut","given":"L.","display":"Castagna, L.","family":"Castagna"},{"display":"Malladi, R.","role":"aut","given":"R.","family":"Malladi"},{"given":"N.","role":"aut","display":"Russell, N.","family":"Russell"},{"role":"aut","given":"A.","display":"Sureda, A.","family":"Sureda"}],"recId":"1699206740","origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"29 August 2016"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"1990","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedDisp":"1990-","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford"}],"recId":"320428796","note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"corporate":[{"display":"European Society for Medical Oncology","role":"isb"}],"disp":"Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow TransplantationAnnals of oncology","id":{"eki":["320428796"],"zdb":["2003498-2"],"issn":["1569-8041"]},"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"part":{"pages":"2251-2257","extent":"7","issue":"12","year":"2016","text":"27(2016), 12, Seite 2251-2257","volume":"27"},"title":[{"subtitle":"official journal of the European Society for Medical Oncology","title":"Annals of oncology","title_sort":"Annals of oncology"}],"pubHistory":["1.1990 -"]}],"note":["Gesehen am 02.06.2020"],"id":{"eki":["1699206740"],"doi":["10.1093/annonc/mdw421"]},"physDesc":[{"extent":"7 S."}],"language":["eng"],"title":[{"subtitle":"a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","title":"Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years","title_sort":"Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years"}]} | ||
| SRT | |a GENADIEVASMYELOABLAT2920 | ||